Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada

April 1, 2026 updated by: PeriPharm
Filling the gap in Canadian evidence on the burden of PROC on QoL is essential. It will help better understand the impact of PROC on multiple aspects of the lives of patients and their caregivers and the real-life hurdles faced by PROC patients and their caregivers. The outputs of this study will help better understand the hurdles and challenges they face and the significant unmet medical need.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

24

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Quebec
      • Montreal, Quebec, Canada, H2Y 1V3
        • PROxy Network, an initiative of PeriPharm Inc.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Patients with ovarian cancer and caregivers of patients with ovarian cancer who are part Ovarian Cancer Canada mailing list.

Description

Patient Inclusion Criteria

  1. ≥18 years old
  2. Patients with PROC who received >1 prior line of therapy identified through a screening survey. PROC will be defined as recurrence less than 6 months after last platinum chemotherapy (i.e. carboplatin or cisplatin)
  3. Ability to read and understand French or English
  4. Signature of ICF

Patients Exclusion Criteria

  1. Patients with PSOC, defined as those who:

    1. Have not progressed within less than 6 months after completion of platinum-based chemotherapy or;
    2. Are still on platinum chemotherapy or;
    3. Receive maintenance therapy.
  2. Patients with platinum-refractory ovarian cancer, defined as not responding or disease progressing during therapy or within three months after the last dose

Caregivers Inclusion Criteria:

  1. ≥18 years old
  2. Current caregiver of a patient with PROC (see definition to be used above) who received >1 prior line of therapy identified through a screening survey.
  3. Ability to read and understand French or English
  4. Signature of ICF.

Caregivers Exclusion Criteria:

  1. Caregivers of patients with PSOC (see definition above)
  2. Caregivers of PROC patients who have passed away
  3. Caregivers of platinum-refractory patients (see definition above)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with PROC part of Ovarian Cancer Canada mailing lists
Other: No intervention
No specific intervention is assess in this study.
Caregiver of PROC patients part of Ovarian Cancer Canada mailing lists
Other: No intervention
No specific intervention is assess in this study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To estimate the quality of life of patient with ovarian cancer
Time Frame: At recruitment
Using the the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) and EuroQol 5-dimendion 5-level (EQ-5D-5L)
At recruitment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient's symptoms assessment
Time Frame: At recruitment
Using the Measure of Ovarian Symptoms and Treatment (MOST-T24 (V2))
At recruitment
Caregiver's Quality of Life
Time Frame: At recruitment
Using the CareGiver Oncology Quality of Life (CarGOQoL) questionnaire
At recruitment
Patients and caregivers work productivity loss and activity impairment
Time Frame: At recruitment
Using the Work Productivity and Activity Impairment (WPAI) questionnaire
At recruitment
Patient's preference in treatment
Time Frame: At recruitment
Using a questionnaire specifically developed for this study based on a literature search, physician input and patient association input.
At recruitment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

PeriPharm

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 15, 2025

Primary Completion (Actual)

April 1, 2026

Study Completion (Actual)

April 1, 2026

Study Registration Dates

First Submitted

June 4, 2025

First Submitted That Met QC Criteria

June 16, 2025

First Posted (Actual)

June 24, 2025

Study Record Updates

Last Update Posted (Actual)

April 7, 2026

Last Update Submitted That Met QC Criteria

April 1, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Ovarian Cancer

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe